Preclinical Evaluation of Recombinant T-cell Receptor Ligand RTL1000 as a Therapeutic Agent in Ischemic Stroke

Recombinant T-cell Receptor Ligand 1000 (RTL1000), a partial human major histocompatibility complex (MHC) molecule coupled to a human myelin peptide, reduces infarct size after experimental stroke in HLA-DRB1*1502 transgenic (DR2-Tg) mice. In this study, we characterized the therapeutic time window...

Full description

Saved in:
Bibliographic Details
Published in:Transl Stroke Res
Main Authors: Zhu, Wenbin, Casper, Amanda, Libal, Nicole L., Murphy, Stephanie J., Bodhankar, Sheetal, Offner, Halina, Alkayed, Nabil J.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4298461/
https://ncbi.nlm.nih.gov/pubmed/25270354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12975-014-0373-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items